Chapman and co‐workers developed an in‐house ELISA made either from 6 TAAs (p53, Nyeso‐1, CAGE, GBU4‐5, Annexin 1, and SOX2) or from 7 TAAs (p53, NY‐ESO‐1, CAGE, GBU4‐5, SOX2, HUD, and MAGE A4) to detect plasma anti‐TAA autoantibodies, but they applied increased levels of plasma anti‐TAA antibodies for early diagnosis of lung cancer [33]. The gene discussed is TP53; the disease is lung carcinoma.